Role of innate host defenses in susceptibility to early-onset neonatal sepsis

Clinics in Perinatology

Volumn 37, Issue 2, 2010, Pages 307-337

  Wynn, James L ^a   Levy, Ofer ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute phase reactant; Early onset sepsis; Innate immunity; Neonate; Neutrophil; Pathogen recognition receptor

Indexed keywords

ACTIVATED PROTEIN C; ACUTE PHASE PROTEIN; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD14 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3 RECEPTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN MD 2; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; SIGNAL PEPTIDE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CHORIOAMNIONITIS; COMPLEMENT ALTERNATIVE PATHWAY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MAST CELL; MATERNAL CARE; NEUTROPENIA; NEWBORN; NEWBORN DEATH; NEWBORN MORTALITY; NEWBORN SEPSIS; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; ANIMAL; DISEASE PREDISPOSITION; IMMUNOLOGY; MICROBIOLOGY; SEPSIS; TIME;

ANIMALS; ANTIGEN-PRESENTING CELLS; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNITY, INNATE; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SEPSIS; TIME FACTORS; TOLL-LIKE RECEPTORS;

EID: 77953522678     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.04.001     Document Type: Review

References (265)

1. Lawn J.E., Cousens S., Zupan J. 4 million neonatal deaths: when? where? why?. Lancet 2005, 365(9462):891-900.
2. Martinot A., Leclerc F., Cremer R., et al. Sepsis in neonates and children: definitions, epidemiology, and outcome. Pediatr Emerg Care 1997, 13(4):277-281.
3. Wynn J.L., Neu J., Moldawer L.L., et al. Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J Perinatol 2009, 29(2):79-88.
4. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7(5):379-390.
5. Adkins B., Leclerc C., Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004, 4(7):553-564.
6. Kollmann T.R., Crabtree J., Rein-Weston A., et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009, 183(11):7150-7160.
7. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8(10):776-787.
8. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348(2):138-150.
9. Abraham E., Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007, 35(10):2408-2416.
10. Cinel I., Dellinger R.P. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007, 20(4):345-352.
11. Jean-Baptiste E. Cellular mechanisms in sepsis. J Intensive Care Med 2007, 22(2):63-72.
12. Sriskandan S., Altmann D.M. The immunology of sepsis. J Pathol 2008, 214(2):211-223.
13. Shah D.K., Doyle L.W., Anderson P.J., et al. Adverse neurodevelopment in preterm infants with postnatal sepsis or necrotizing enterocolitis is mediated by white matter abnormalities on magnetic resonance imaging at term. J Pediatr 2008, 153(2):170-175. 175. e171.
14. Palazzi D., Klein J., Baker C. Bacterial sepsis and meningitis. Infectious diseases of the fetus and newborn infant 2006, 247-295. Elsevier Saunders, Philadelphia. 6th edition. J.S. Remington, O.J. Klein, C.B. Wilson (Eds.).
15. Benitz W.E., Gould J.B., Druzin M.L. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics 1999, 103(6):e77.
16. Bizzarro M.J., Dembry L.M., Baltimore R.S., et al. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008, 121(4):689-696.
17. Hyde T.B., Hilger T.M., Reingold A., et al. Trends in incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics 2002, 110(4):690-695.
18. Moore M.R., Schrag S.J., Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003, 3(4):201-213.
19. Anthony B.F., Okada D.M. The emergence of group B streptococci in infections of the newborn infant. Annu Rev Med 1977, 28:355-369.
20. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. Pediatrics 1992, 90(5):775-778.
21. Centers for Disease Control and Prevention (CDC) Trends in perinatal group B streptococcal disease-United States, 2000-2006. MMWR Morb Mortal Wkly Rep 2009, 58(5):109-112.
22. Cotten C.M., Taylor S., Stoll B., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009, 123(1):58-66.
23. Stoll B.J., Hansen N.I., Higgins R.D., et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005, 24(7):635-639.
24. Stoll B.J., Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Semin Perinatol 2003, 27(4):293-301.
25. Stoll B.J., Hansen N., Fanaroff A.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347(4):240-247.
26. Barton L., Hodgman J.E., Pavlova Z. Causes of death in the extremely low birth weight infant. Pediatrics 1999, 103(2):446-451.
27. Holladay S.D., Smialowicz R.J. Development of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure. Environ Health Perspect 2000, 108(Suppl 3):463-473.
28. Koga K., Aldo P.B., Mor G. Toll-like receptors and pregnancy: trophoblast as modulators of the immune response. J Obstet Gynaecol Res 2009, 35(2):191-202.
29. Sampson J.E., Theve R.P., Blatman R.N., et al. Fetal origin of amniotic fluid polymorphonuclear leukocytes. Am J Obstet Gynecol 1997, 176(1 Pt 1):77-81.
30. Gotsch F., Romero R., Kusanovic J.P., et al. The fetal inflammatory response syndrome. Clin Obstet Gynecol 2007, 50(3):652-683.
31. Saji F., Samejima Y., Kamiura S., et al. Cytokine production in chorioamnionitis. J Reprod Immunol 2000, 47(2):185-196.
32. Kemp B., Winkler M., Maas A., et al. Cytokine concentrations in the amniotic fluid during parturition at term: correlation to lower uterine segment values and to labor. Acta Obstet Gynecol Scand 2002, 81(10):938-942.
33. Kallapur S.G., Willet K.E., Jobe A.H., et al. Intra-amniotic endotoxin: chorioamnionitis precedes lung maturation in preterm lambs. Am J Physiol Lung Cell Mol Physiol 2001, 280(3):L527-L536.
34. Erez O., Romero R., Tarca A.L., et al. Differential expression pattern of genes encoding for anti-microbial peptides in the fetal membranes of patients with spontaneous preterm labor and intact membranes and those with preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med 2009, 22(12):1103-1115.
35. Leth-Larsen R., Floridon C., Nielsen O., et al. Surfactant protein D in the female genital tract. Mol Hum Reprod 2004, 10(3):149-154.
36. King A.E., Kelly R.W., Sallenave J.M., et al. Innate immune defences in the human uterus during pregnancy. Placenta 2007, 28(11-12):1099-1106.
37. Tollin M., Bergsson G., Kai-Larsen Y., et al. Vernix caseosa as a multi-component defence system based on polypeptides, lipids and their interactions. Cell Mol Life Sci 2005, 62(19-20):2390-2399.
38. Visscher M.O., Narendran V., Pickens W.L., et al. Vernix caseosa in neonatal adaptation. J Perinatol 2005, 25(7):440-446.
39. Rutter N. Clinical consequences of an immature barrier. Semin Neonatol 2000, 5(4):281-287.
40. Evans N.J., Rutter N. Development of the epidermis in the newborn. Biol Neonate 1986, 49(2):74-80.
41. Kalia Y.N., Nonato L.B., Lund C.H., et al. Development of skin barrier function in premature infants. J Invest Dermatol 1998, 111(2):320-326.
42. Marchini G., Lindow S., Brismar H., et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol 2002, 147(6):1127-1134.
43. Marchini G., Nelson A., Edner J., et al. Erythema toxicum neonatorum is an innate immune response to commensal microbes penetrated into the skin of the newborn infant. Pediatr Res 2005, 58(3):613-616.
44. Lewis D., Wilson C. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. Infectious diseases of the fetus and newborn infant 2006, 87-210. Elsevier Saunders, Philadelphia. 6th edition. J.S. Remington, O.J. Klein, C.B. Wilson (Eds.).
45. Martin C.R., Walker W.A. Probiotics: role in pathophysiology and prevention in necrotizing enterocolitis. Semin Perinatol 2008, 32(2):127-137.
46. Sharma R., Tepas J.J., Hudak M.L., et al. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg 2007, 42(3):454-461.
47. Neu J. Gastrointestinal maturation and implications for infant feeding. Early Hum Dev 2007, 83(12):767-775.
48. Bartlett J.A., Fischer A.J., McCray P.B. Innate immune functions of the airway epithelium. Contrib Microbiol 2008, 15:147-163.
49. Nathe K.E., Parad R., Van Marter L.J., et al. Endotoxin-directed innate immunity in tracheal aspirates of mechanically ventilated human neonates. Pediatr Res 2009, 66(2):191-196.
50. Pfister R.H., Soll R.F. New synthetic surfactants: the next generation?. Biol Neonate 2005, 87(4):338-344.
51. Starner T.D., Agerberth B., Gudmundsson G.H., et al. Expression and activity of beta-defensins and LL-37 in the developing human lung. J Immunol 2005, 174(3):1608-1615.
52. Brown G.D. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006, 6(1):33-43.
53. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009, 21(4):317-337.
54. Kumagai Y., Takeuchi O., Akira S. Pathogen recognition by innate receptors. J Infect Chemother 2008, 14(2):86-92.
55. Trinchieri G., Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7(3):179-190.
56. Krumbiegel D., Zepp F., Meyer C.U. Combined toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum Immunol 2007, 68(10):813-822.
57. Levy O., Zarember K.A., Roy R.M., et al. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004, 173(7):4627-4634.
58. Forster-Waldl E., Sadeghi K., Tamandl D., et al. Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res 2005, 58(1):121-124.
59. Zhang J.P., Chen C., Yang Y. Zhonghua Er Ke Za Zhi 2007, 45(2):130-133. [in Chinese].
60. Hartel C., Rupp J., Hoegemann A., et al. 159C>T CD14 genotype-functional effects on innate immune responses in term neonates. Hum Immunol 2008, 69(6):338-343.
61. Mollen K.P., Gribar S.C., Anand R.J., et al. Increased expression and internalization of the endotoxin coreceptor CD14 in enterocytes occur as an early event in the development of experimental necrotizing enterocolitis. J Pediatr Surg 2008, 43(6):1175-1181.
62. Hubacek J.A., Stuber F., Frohlich D., et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001, 29(3):557-561.
63. Behrendt D., Dembinski J., Heep A., et al. Lipopolysaccharide binding protein in preterm infants. Arch Dis Child Fetal Neonatal Ed 2004, 89(6):F551-F554.
64. Berner R., Furll B., Stelter F., et al. Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 2002, 9(2):440-445.
65. Blanco A., Solis G., Arranz E., et al. Serum levels of CD14 in neonatal sepsis by gram-positive and gram-negative bacteria. Acta Paediatr 1996, 85(6):728-732.
66. Warren S.E., Mao D.P., Rodriguez A.E., et al. Multiple nod-like receptors activate caspase 1 during Listeria monocytogenes infection. J Immunol 2008, 180(11):7558-7564.
67. Goldbach-Mansky R., Dailey N.J., Canna S.W., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355(6):581-592.
68. Szebeni B., Szekeres R., Rusai K., et al. Genetic polymorphisms of CD14, toll-like receptor 4, and caspase-recruitment domain 15 are not associated with necrotizing enterocolitis in very low birth weight infants. J Pediatr Gastroenterol Nutr 2006, 42(1):27-31.
69. Bochud P.Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359(17):1766-1777.
70. Wurfel M.M., Gordon A.C., Holden T.D., et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008, 178(7):710-720.
71. Agnese D.M., Calvano J.E., Hahm S.J., et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002, 186(10):1522-1525.
72. Lorenz E., Mira J.P., Cornish K.L., et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000, 68(11):6398-6401.
73. von Bernuth H., Picard C., Jin Z., et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321(5889):691-696.
74. Picard C., Puel A., Bonnet M., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299(5615):2076-2079.
75. Zhang S.Y., Jouanguy E., Ugolini S., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317(5844):1522-1527.
76. Mockenhaupt F.P., Cramer J.P., Hamann L., et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. J Commun Dis 2006, 38(3):230-245.
77. Faber J., Meyer C.U., Gemmer C., et al. Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. Pediatr Infect Dis J 2006, 25(1):80-81.
78. Ku C.L., von Bernuth H., Picard C., et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007, 204(10):2407-2422.
79. Wynn J.L., Scumpia P.O., Delano M.J., et al. Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock 2007, 28(6):675-683.
80. Wynn J.L., Scumpia P.O., Winfield R.D., et al. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood 2008, 112(5):1750-1758.
81. Salomao R., Brunialti M.K., Gomes N.E., et al. Toll-like receptor pathway signaling is differently regulated in neutrophils and peripheral mononuclear cells of patients with sepsis, severe sepsis, and septic shock. Crit Care Med 2009, 37(1):132-139.
82. Al-Hertani W., Yan S.R., Byers D.M., et al. Human newborn polymorphonuclear neutrophils exhibit decreased levels of MyD88 and attenuated p38 phosphorylation in response to lipopolysaccharide. Clin Invest Med 2007, 30(2):E44-E53.
83. Sadeghi K., Berger A., Langgartner M., et al. Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. J Infect Dis 2007, 195(2):296-302.
84. Yan S.R., Qing G., Byers D.M., et al. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect Immun 2004, 72(3):1223-1229.
85. Ehlers M.R. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect 2000, 2(3):289-294.
86. McEvoy L.T., Zakem-Cloud H., Tosi M.F. Total cell content of CR3 (CD11b/CD18) and LFA-1 (CD11a/CD18) in neonatal neutrophils: relationship to gestational age. Blood 1996, 87(9):3929-3933.
87. Buhrer C., Graulich J., Stibenz D., et al. L-selectin is down-regulated in umbilical cord blood granulocytes and monocytes of newborn infants with acute bacterial infection. Pediatr Res 1994, 36(6):799-804.
88. Kim S.K., Keeney S.E., Alpard S.K., et al. Comparison of L-selectin and CD11b on neutrophils of adults and neonates during the first month of life. Pediatr Res 2003, 53(1):132-136.
89. Nupponen I., Pesonen E., Andersson S., et al. Neutrophil activation in preterm infants who have respiratory distress syndrome. Pediatrics 2002, 110(1 Pt 1):36-41.
90. Nathan C.F. Secretory products of macrophages. J Clin Invest 1987, 79(2):319-326.
91. Willems F., Vollstedt S., Suter M. Phenotype and function of neonatal DC. Eur J Immunol 2009, 39(1):26-35.
92. Angelone D.F., Wessels M.R., Coughlin M., et al. Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatr Res 2006, 60(2):205-209.
93. Levy O., Coughlin M., Cronstein B.N., et al. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 2006, 177(3):1956-1966.
94. Marodi L. Innate cellular immune responses in newborns. Clin Immunol 2006, 118(2-3):137-144.
95. Marodi L. Down-regulation of Th1 responses in human neonates. Clin Exp Immunol 2002, 128(1):1-2.
96. Ottenhoff T.H., De Boer T., van Dissel J.T., et al. Human deficiencies in type-1 cytokine receptors reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Adv Exp Med Biol 2003, 531:279-294.
97. Whitley R., Arvin A., Prober C., et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991, 324(7):450-454.
98. Jones C.A., Holloway J.A., Warner J.O. Phenotype of fetal monocytes and B lymphocytes during the third trimester of pregnancy. J Reprod Immunol 2002, 56(1-2):45-60.
99. Hunt D.W., Huppertz H.I., Jiang H.J., et al. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood 1994, 84(12):4333-4343.
100. Velilla P.A., Rugeles M.T., Chougnet C.A. Defective antigen-presenting cell function in human neonates. Clin Immunol 2006, 121(3):251-259.
101. Krumbiegel D., Rohr J., Schmidtke P., et al. Efficient maturation and cytokine production of neonatal DCs requires combined proinflammatory signals. Clin Dev Immunol 2005, 12(2):99-105.
102. Wong O.H., Huang F.P., Chiang A.K. Differential responses of cord and adult blood-derived dendritic cells to dying cells. Immunology 2005, 116(1):13-20.
103. Salio M., Dulphy N., Renneson J., et al. Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. Int Immunol 2003, 15(10):1265-1273.
104. Hallwirth U., Pomberger G., Zaknun D., et al. Monocyte phagocytosis as a reliable parameter for predicting early-onset sepsis in very low birthweight infants. Early Hum Dev 2002, 67(1-2):1-9.
105. Klein R.B., Fischer T.J., Gard S.E., et al. Decreased mononuclear and polymorphonuclear chemotaxis in human newborns, infants, and young children. Pediatrics 1977, 60(4):467-472.
106. Chelvarajan L., Popa D., Liu Y., et al. Molecular mechanisms underlying anti-inflammatory phenotype of neonatal splenic macrophages. J Leukoc Biol 2007, 82(2):403-416.
107. Aikio O., Vuopala K., Pokela M.L., et al. Diminished inducible nitric oxide synthase expression in fulminant early-onset neonatal pneumonia. Pediatrics 2000, 105(5):1013-1019.
108. Levy O., Jean-Jacques R.M., Cywes C., et al. Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release. Infect Immun 2003, 71(11):6344-6353.
109. Levy O., Suter E.E., Miller R.L., et al. Unique efficacy of toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006, 108(4):1284-1290.
110. Vekemans J., Amedei A., Ota M.O., et al. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol 2001, 31(5):1531-1535.
111. Dale D.C., Boxer L., Liles W.C. The phagocytes: neutrophils and monocytes. Blood 2008, 112(4):935-945.
112. Urlichs F., Speer C. Neutrophil function in preterm and term infants. NeoReviews 2004, 5:e417-e430.
113. Weinschenk N.P., Farina A., Bianchi D.W. Premature infants respond to early-onset and late-onset sepsis with leukocyte activation. J Pediatr 2000, 137(3):345-350.
114. Engle W.A., McGuire W.A., Schreiner R.L., et al. Neutrophil storage pool depletion in neonates with sepsis and neutropenia. J Pediatr 1988, 113(4):747-749.
115. Christensen R.D., Rothstein G. Exhaustion of mature marrow neutrophils in neonates with sepsis. J Pediatr 1980, 96(2):316-318.
116. Christensen R.D., Bradley P.P., Rothstein G. The leukocyte left shift in clinical and experimental neonatal sepsis. J Pediatr 1981, 98(1):101-105.
117. Squire E., Favara B., Todd J. Diagnosis of neonatal bacterial infection: hematologic and pathologic findings in fatal and nonfatal cases. Pediatrics 1979, 64(1):60-64.
118. Doron M.W., Makhlouf R.A., Katz V.L., et al. Increased incidence of sepsis at birth in neutropenic infants of mothers with preeclampsia. J Pediatr 1994, 125(3):452-458.
119. Gray P.H., Rodwell R.L. Neonatal neutropenia associated with maternal hypertension poses a risk for nosocomial infection. Eur J Pediatr 1999, 158(1):71-73. [Epub 2008 Dec 11]. PMID: 19078971.
120. Paul D.A., Leef K.H., Sciscione A., et al. Preeclampsia does not increase the risk for culture proven sepsis in very low birth weight infants. Am J Perinatol 1999, 16(7):365-372.
121. Teng R.J., Wu T.J., Garrison R.D., et al. Early neutropenia is not associated with an increased rate of nosocomial infection in very low-birth-weight infants. J Perinatol 2009, 29(3):219-224.
122. Christensen R.D., Henry E., Wiedmeier S.E., et al. Low blood neutrophil concentrations among extremely low birth weight neonates: data from a multihospital health-care system. J Perinatol 2006, 26(11):682-687.
123. Turkmen M., Satar M., Atici A. Neutrophil chemotaxis and random migration in preterm and term infants with sepsis. Am J Perinatol 2000, 17(2):107-112.
124. Merry C., Puri P., Reen D.J. Defective neutrophil actin polymerisation and chemotaxis in stressed newborns. J Pediatr Surg 1996, 31(4):481-485.
125. Meade V.M., Barese C.N., Kim C., et al. Rac2 concentrations in umbilical cord neutrophils. Biol Neonate 2006, 90(3):156-159.
126. Xing Z., Gauldie J., Cox G., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101(2):311-320.
127. Hickey M.J., Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol 2009, 9(5):364-375.
128. Yektaei-Karin E., Moshfegh A., Lundahl J., et al. The stress of birth enhances in vitro spontaneous and IL-8-induced neutrophil chemotaxis in the human newborn. Pediatr Allergy Immunol 2007, 18(8):643-651.
129. Zentay Z., Sharaf M., Qadir M., et al. Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: role of neutrophil interleukin-8 release. Pediatr Res 1999, 46(4):406-410.
130. Molloy E.J., O'Neill A.J., Grantham J.J., et al. Labor promotes neonatal neutrophil survival and lipopolysaccharide responsiveness. Pediatr Res 2004, 56(1):99-103.
131. Shen C.M., Lin S.C., Niu D.M., et al. Labour increases the surface expression of two toll-like receptors in the cord blood monocytes of healthy term newborns. Acta Paediatr 2009, 98(6):959-962.
132. Linderkamp O., Ruef P., Brenner B., et al. Passive deformability of mature, immature, and active neutrophils in healthy and septicemic neonates. Pediatr Res 1998, 44(6):946-950.
133. Mease A.D., Burgess D.P., Thomas P.J. Irreversible neutrophil aggregation. A mechanism of decreased newborn neutrophil chemotactic response. Am J Pathol 1981, 104(1):98-102.
134. Levy O., Martin S., Eichenwald E., et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 1999, 104(6):1327-1333.
135. Kjeldsen L., Sengelov H., Lollike K., et al. Granules and secretory vesicles in human neonatal neutrophils. Pediatr Res 1996, 40(1):120-129.
136. Drossou V., Kanakoudi F., Tzimouli V., et al. Impact of prematurity, stress and sepsis on the neutrophil respiratory burst activity of neonates. Biol Neonate 1997, 72(4):201-209.
137. Shigeoka A.O., Santos J.I., Hill H.R. Functional analysis of neutrophil granulocytes from healthy, infected, and stressed neonates. J Pediatr 1979, 95(3):454-460.
138. Wright W.C., Ank B.J., Herbert J., et al. Decreased bactericidal activity of leukocytes of stressed newborn infants. Pediatrics 1975, 56(4):579-584.
139. Bialek R., Bartmann P. Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants?. Infection 1998, 26(6):375-378.
140. Falconer A.E., Carr R., Edwards S.W. Impaired neutrophil phagocytosis in preterm neonates: lack of correlation with expression of immunoglobulin or complement receptors. Biol Neonate 1995, 68(4):264-269.
141. Allgaier B., Shi M., Luo D., et al. Spontaneous and Fas-mediated apoptosis are diminished in umbilical cord blood neutrophils compared with adult neutrophils. J Leukoc Biol 1998, 64(3):331-336.
142. Hanna N., Vasquez P., Pham P., et al. Mechanisms underlying reduced apoptosis in neonatal neutrophils. Pediatr Res 2005, 57(1):56-62.
143. Koenig J.M., Stegner J.J., Schmeck A.C., et al. Neonatal neutrophils with prolonged survival exhibit enhanced inflammatory and cytotoxic responsiveness. Pediatr Res 2005, 57(3):424-429.
144. Ohman L., Tullus K., Katouli M., et al. Correlation between susceptibility of infants to infections and interaction with neutrophils of Escherichia coli strains causing neonatal and infantile septicemia. J Infect Dis 1995, 171(1):128-133.
145. Clark S.R., Ma A.C., Tavener S.A., et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007, 13(4):463-469.
146. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303(5663):1532-1535. [Epub 2009 Feb 12]. PMID: 19221037.
147. Fuchs T.A., Abed U., Goosmann C., et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176(2):231-241.
148. Yost C.C., Cody M.J., Harris E.S., et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood 2009, 113(25):6419-6427.
149. Marshall J.S., Jawdat D.M. Mast cells in innate immunity. J Allergy Clin Immunol 2004, 114(1):21-27.
150. Damsgaard T.E., Nielsen B.W., Henriques U., et al. Histamine releasing cells of the newborn. Mast cells from the umbilical cord matrix and basophils from cord blood. Pediatr Allergy Immunol 1996, 7(2):83-90.
151. Mazzoni A., Young H.A., Spitzer J.H., et al. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001, 108(12):1865-1873.
152. Nelson A., Ulfgren A.K., Edner J., et al. Urticaria neonatorum: accumulation of tryptase-expressing mast cells in the skin lesions of newborns with erythema toxicum. Pediatr Allergy Immunol 2007, 18(8):652-658.
153. Drossou V., Kanakoudi F., Diamanti E., et al. Concentrations of main serum opsonins in early infancy. Arch Dis Child Fetal Neonatal Ed 1995, 72(3):F172-F175.
154. Miller M.E., Stiehm E.R. Phagocytic, opsonic and immunoglobulin studies in newborns. Calif Med 1973, 119(2):43-63.
155. Wolach B., Dolfin T., Regev R., et al. The development of the complement system after 28 weeks' gestation. Acta Paediatr 1997, 86(5):523-527.
156. Notarangelo L.D., Chirico G., Chiara A., et al. Activity of classical and alternative pathways of complement in preterm and small for gestational age infants. Pediatr Res 1984, 18(3):281-285.
157. Lassiter H.A., Watson S.W., Seifring M.L., et al. Complement factor 9 deficiency in serum of human neonates. J Infect Dis 1992, 166(1):53-57.
158. Levy O., Sisson R.B., Kenyon J., et al. Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo. Infect Immun 2000, 68(9):5120-5125.
159. Zilow E.P., Hauck W., Linderkamp O., et al. Alternative pathway activation of the complement system in preterm infants with early onset infection. Pediatr Res 1997, 41(3):334-339.
160. Zilow G., Zilow E.P., Burger R., et al. Complement activation in newborn infants with early onset infection. Pediatr Res 1993, 34(2):199-203.
161. Frakking F.N., Brouwer N., van Eijkelenburg N.K., et al. Low mannose-binding lectin (MBL) levels in neonates with pneumonia and sepsis. Clin Exp Immunol 2007, 150(2):255-262.
162. Dzwonek A.B., Neth O.W., Thiebaut R., et al. The role of mannose-binding lectin in susceptibility to infection in preterm neonates. Pediatr Res 2008, 63(6):680-685.
163. Nupponen I., Andersson S., Jarvenpaa A.L., et al. Neutrophil CD11b expression and circulating interleukin-8 as diagnostic markers for early-onset neonatal sepsis. Pediatrics 2001, 108(1):E12.
164. Berger M., O'Shea J., Cross A.S., et al. Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest 1984, 74(5):1566-1571.
165. Snyderman R., Goetzl E.J. Molecular and cellular mechanisms of leukocyte chemotaxis. Science 1981, 213(4510):830-837.
166. Vogt W. Anaphylatoxins: possible roles in disease. Complement 1986, 3(3):177-188.
167. Anderson D.C., Rothlein R., Marlin S.D., et al. Impaired transendothelial migration by neonatal neutrophils: abnormalities of Mac-1 (CD11b/CD18)-dependent adherence reactions. Blood 1990, 76(12):2613-2621.
168. Nybo M., Sorensen O., Leslie R., et al. Reduced expression of C5a receptors on neutrophils from cord blood. Arch Dis Child Fetal Neonatal Ed 1998, 78(2):F129-F132.
169. Ng P.C. Diagnostic markers of infection in neonates. Arch Dis Child Fetal Neonatal Ed 2004, 89(3):F229-F235.
170. Ng P.C., Li K., Wong R.P., et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed 2003, 88(3):F209-F213.
171. Bozza F.A., Salluh J.I., Japiassu A.M., et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007, 11(2):R49.
172. Hodge G., Hodge S., Haslam R., et al. Rapid simultaneous measurement of multiple cytokines using 100 microl sample volumes-association with neonatal sepsis. Clin Exp Immunol 2004, 137(2):402-407.
173. Demirjian A., Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol 2009, 39(1):36-46.
174. Ahrens P., Kattner E., Kohler B., et al. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res 2004, 55(4):652-656.
175. Reiman M., Kujari H., Ekholm E., et al. Interleukin-6 polymorphism is associated with chorioamnionitis and neonatal infections in preterm infants. J Pediatr 2008, 153(1):19-24.
176. Gopel W., Hartel C., Ahrens P., et al. Interleukin-6-174-genotype, sepsis and cerebral injury in very low birth weight infants. Genes Immun 2006, 7(1):65-68.
177. Baier R.J., Loggins J., Yanamandra K. IL-10, IL-6 and CD14 polymorphisms and sepsis outcome in ventilated very low birth weight infants. BMC Med 2006, 4:10.
178. Schueller A.C., Heep A., Kattner E., et al. Prevalence of two tumor necrosis factor gene polymorphisms in premature infants with early onset sepsis. Biol Neonate 2006, 90(4):229-232.
179. Treszl A., Kocsis I., Szathmari M., et al. Genetic variants of TNF-[FC12]a, IL-1beta, IL-4 receptor [FC12]a-chain, IL-6 and IL-10 genes are not risk factors for sepsis in low-birth-weight infants. Biol Neonate 2003, 83(4):241-245.
180. Chauhan M., McGuire W. Interleukin-6 (-174C) polymorphism and the risk of sepsis in very low birth weight infants: meta-analysis. Arch Dis Child Fetal Neonatal Ed 2008, 93(6):F427-F429.
181. Zhao J., Kim K.D., Yang X., et al. Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci U S A 2008, 105(21):7528-7533.
182. Cusumano V., Mancuso G., Genovese F., et al. Neonatal hypersusceptibility to endotoxin correlates with increased tumor necrosis factor production in mice. J Infect Dis 1997, 176(1):168-176.
183. Wong H.R., Doughty L.A., Wedel N., et al. Plasma bactericidal/permeability-increasing protein concentrations in critically ill children with the sepsis syndrome. Pediatr Infect Dis J 1995, 14(12):1087-1091.
184. Romeo M.G., Tina L.G., Sciacca A., et al. Pediatr Med Chir 1995, 17(6):563-566. [in Italian].
185. Kalayci A.G., Adam B., Yilmazer F., et al. The value of immunoglobulin and complement levels in the early diagnosis of neonatal sepsis. Acta Paediatr 1997, 86(9):999-1002.
186. Dyke M.P., Forsyth K.D. Decreased plasma fibronectin concentrations in preterm infants with septicaemia. Arch Dis Child 1993, 68(5 Spec No):557-560.
187. Benitz W.E., Han M.Y., Madan A., et al. Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics 1998, 102(4):E41.
188. Madden N.P., Levinsky R.J., Bayston R., et al. Surgery, sepsis, and nonspecific immune function in neonates. J Pediatr Surg 1989, 24(6):562-566.
189. Rivers R.P., Cattermole H.E., Wright I. The expression of surface tissue factor apoprotein by blood monocytes in the course of infections in early infancy. Pediatr Res 1992, 31(6):567-573.
190. Markiewski M.M., Nilsson B., Ekdahl K.N., et al. Complement and coagulation: strangers or partners in crime?. Trends Immunol 2007, 28(4):184-192.
191. Aronis S., Platokouki H., Photopoulos S., et al. Indications of coagulation and/or fibrinolytic system activation in healthy and sick very-low-birth-weight neonates. Biol Neonate 1998, 74(5):337-344.
192. Roman J., Velasco F., Fernandez F., et al. Coagulation, fibrinolytic and kallikrein systems in neonates with uncomplicated sepsis and septic shock. Haemostasis 1993, 23(3):142-148.
193. Lauterbach R., Pawlik D., Radziszewska R., et al. Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns. Eur J Pediatr 2006, 165(9):585-589.
194. Grewal P.K., Uchiyama S., Ditto D., et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008, 14(6):648-655.
195. Guida J.D., Kunig A.M., Leef K.H., et al. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response?. Pediatrics 2003, 111(6 Pt 1):1411-1415.
196. Sola M.C., Del Vecchio A., Rimsza L.M. Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Clin Perinatol 2000, 27(3):655-679.
197. Spear M.L., Stefano J.L., Fawcett P., et al. Soluble interleukin-2 receptor as a predictor of neonatal sepsis. J Pediatr 1995, 126(6):982-985.
198. Hathaway W.E., Mull M.M., Pechet G.S. Disseminated intravascular coagulation in the newborn. Pediatrics 1969, 43(2):233-240.
199. Malek A., Sager R., Schneider H. Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy. Am J Reprod Immunol 1994, 32(1):8-14.
200. Fanaroff A.A., Korones S.B., Wright L.L., et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1994, 330(16):1107-1113.
201. Sandberg K., Fasth A., Berger A., et al. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. J Pediatr 2000, 137(5):623-628.
202. Ballow M., Cates K.L., Rowe J.C., et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986, 20(9):899-904.
203. Conway S.P., Dear P.R., Smith I. Immunoglobulin profile of the preterm baby. Arch Dis Child 1985, 60(3):208-212.
204. Bonagura V.R., Marchlewski R., Cox A., et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008, 122(1):210-212.
205. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3(9):710-720.
206. Yoshio H., Lagercrantz H., Gudmundsson G.H., et al. First line of defense in early human life. Semin Perinatol 2004, 28(4):304-311.
207. Schrama A.J., de Beaufort A.J., Poorthuis B.J., et al. Secretory phospholipase A(2) in newborn infants with sepsis. J Perinatol 2008, 28(4):291-296.
208. Kingsmore S.F., Kennedy N., Halliday H.L., et al. Identification of diagnostic biomarkers for infection in premature neonates. Mol Cell Proteomics 2008, 7(10):1863-1875.
209. Ayabe T., Ashida T., Kohgo Y., et al. The role of Paneth cells and their antimicrobial peptides in innate host defense. Trends Microbiol 2004, 12(8):394-398.
210. Holzl M.A., Hofer J., Steinberger P., et al. Host antimicrobial proteins as endogenous immunomodulators. Immunol Lett 2008, 119(1-2):4-11.
211. Selsted M.E., Ouellette A.J. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005, 6(6):551-557.
212. Strunk T., Doherty D., Richmond P., et al. Reduced levels of antimicrobial proteins and peptides in human cord blood plasma. Arch Dis Child Fetal Neonatal Ed 2009, 94(3):F230-F231.
213. Ihi T., Nakazato M., Mukae H., et al. Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin Infect Dis 1997, 25(5):1134-1140.
214. Thomas N.J., Carcillo J.A., Doughty L.A., et al. Plasma concentrations of defensins and lactoferrin in children with severe sepsis. Pediatr Infect Dis J 2002, 21(1):34-38.
215. Nupponen I., Turunen R., Nevalainen T., et al. Extracellular release of bactericidal/permeability-increasing protein in newborn infants. Pediatr Res 2002, 51(6):670-674.
216. Michalek J., Svetlikova P., Fedora M., et al. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med 2007, 33(12):2158-2164.
217. Dorschner R.A., Lin K.H., Murakami M., et al. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res 2003, 53(4):566-572.
218. Yoshio H., Tollin M., Gudmundsson G.H., et al. Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res 2003, 53(2):211-216.
219. Baker S.M., Balo N.N., Abdel Aziz F.T. Is vernix caseosa a protective material to the newborn? A biochemical approach. Indian J Pediatr 1995, 62(2):237-239.
220. Larson A.A., Dinulos J.G. Cutaneous bacterial infections in the newborn. Curr Opin Pediatr 2005, 17(4):481-485.
221. Ricci E., Malacrida S., Zanchetta M., et al. Role of beta-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2009, 51(1):13-19.
222. Walker V.P., Akinbi H.T., Meinzen-Derr J., et al. Host defense proteins on the surface of neonatal skin: implications for innate immunity. J Pediatr 2008, 152(6):777-781.
223. Espinoza J., Chaiworapongsa T., Romero R., et al. Antimicrobial peptides in amniotic fluid: defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes. J Matern Fetal Neonatal Med 2003, 13(1):2-21.
224. Schaller-Bals S., Schulze A., Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med 2002, 165(7):992-995.
225. Revenis M.E., Kaliner M.A. Lactoferrin and lysozyme deficiency in airway secretions: association with the development of bronchopulmonary dysplasia. J Pediatr 1992, 121(2):262-270.
226. Kai-Larsen Y., Bergsson G., Gudmundsson G.H., et al. Antimicrobial components of the neonatal gut affected upon colonization. Pediatr Res 2007, 61(5 Pt 1):530-536.
227. Salzman N.H., Polin R.A., Harris M.C., et al. Enteric defensin expression in necrotizing enterocolitis. Pediatr Res 1998, 44(1):20-26.
228. Armogida S.A., Yannaras N.M., Melton A.L., et al. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc 2004, 25(5):297-304.
229. Chan G.M., Lee M.L., Rechtman D.J. Effects of a human milk-derived human milk fortifier on the antibacterial actions of human milk. Breastfeed Med 2007, 2(4):205-208.
230. Newburg D.S., Walker W.A. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res 2007, 61(1):2-8.
231. Schrag S.J., Zell E.R., Lynfield R., et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002, 347(4):233-239.
232. Cararach V., Botet F., Sentis J., et al. Administration of antibiotics to patients with rupture of membranes at term: a prospective, randomized, multicentric study. Collaborative Group on PROM. Acta Obstet Gynecol Scand 1998, 77(3):298-302.
233. Pylipow M., Gaddis M., Kinney J.S. Selective intrapartum prophylaxis for group B streptococcus colonization: management and outcome of newborns. Pediatrics 1994, 93(4):631-635.
234. Segel S.Y., Miles A.M., Clothier B., et al. Duration of antibiotic therapy after preterm premature rupture of fetal membranes. Am J Obstet Gynecol 2003, 189(3):799-802.
235. Johnston M.M., Sanchez-Ramos L., Vaughn A.J., et al. Antibiotic therapy in preterm premature rupture of membranes: a randomized, prospective, double-blind trial. Am J Obstet Gynecol 1990, 163(3):743-747.
236. Hopkins L., Smaill F. Antibiotic regimens for management of intraamniotic infection. Cochrane Database Syst Rev 2002, 3. CD003254.
237. Cohen-Wolkowiez M., Benjamin D.K., Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr Opin Pediatr 2009, 21(2):177-181.
238. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34(1):17-60.
239. Venkataseshan S., Dutta S., Ahluwalia J., et al. Low plasma protein C values predict mortality in low birth weight neonates with septicemia. Pediatr Infect Dis J 2007, 26(8):684-688.
240. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369(9564):836-843.
241. Mohan P., Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev 2003, 4. CD003956.
242. Carr R., Modi N., Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003, 3. CD003066.
243. Carr R., Brocklehurst P., Dore C.J., et al. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 2009, 373(9659):226-233.
244. Buhimschi C.S., Bhandari V., Hamar B.D., et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med 2007, 4(1):e18.
245. Buhimschi C.S., Bhandari V., Han Y.W., et al. Using proteomics in perinatal and neonatal sepsis: hopes and challenges for the future. Curr Opin Infect Dis 2009, 22(3):235-243.
246. Ng P.C., Li G., Chui K.M., et al. Quantitative measurement of monocyte HLA-DR expression in the identification of early-onset neonatal infection. Biol Neonate 2006, 89(2):75-81.
247. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24(12):1551-1557.
248. Hirsch T., Metzig M., Niederbichler A., et al. Role of host defense peptides of the innate immune response in sepsis. Shock 2008, 30(2):117-126.
249. Fukumoto K., Nagaoka I., Yamataka A., et al. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr Surg Int 2005, 21(1):20-24.
250. Manzoni P., Rinaldi M., Cattani S., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009, 302(13):1421-1428.
251. Brubaker J.O., Montaner L.J. Role of interleukin-13 in innate and adaptive immunity. Cell Mol Biol (Noisy-le-grand) 2001, 47(4):637-651.
252. Koj A. Termination of acute-phase response: role of some cytokines and anti-inflammatory drugs. Gen Pharmacol 1998, 31(1):9-18.
253. Sikora J.P., Chlebna-Sokol D., Krzyzanska-Oberbek A. Proinflammatory cytokines (IL-6, IL-8), cytokine inhibitors (IL-6sR, sTNFRII) and anti-inflammatory cytokines (IL-10, IL-13) in the pathogenesis of sepsis in newborns and infants. Arch Immunol Ther Exp (Warsz) 2001, 49(5):399-404.
254. Opal S.M., Esmon C.T. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003, 7(1):23-38.
255. Trepicchio W.L., Bozza M., Pedneault G., et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996, 157(8):3627-3634.
256. Wang P., Wu P., Siegel M.I., et al. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995, 270(16):9558-9563.
257. Dollner H., Vatten L., Linnebo I., et al. Inflammatory mediators in umbilical plasma from neonates who develop early-onset sepsis. Biol Neonate 2001, 80(1):41-47.
258. Cunnington A., Nadel S. New therapies for sepsis. Curr Top Med Chem 2008, 8(7):603-614.
259. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 2001, 18(1):1-9.
260. Chawla D., Agarwal R., Deorari A.K., et al. Retinopathy of prematurity. Indian J Pediatr 2008, 75(1):73-76.
261. Ikegami M., Carter K., Bishop K., et al. Intratracheal recombinant surfactant protein d prevents endotoxin shock in the newborn preterm lamb. Am J Respir Crit Care Med 2006, 173(12):1342-1347.
262. Doss M., White M.R., Tecle T., et al. Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J Immunol 2009, 182(12):7878-7887.
263. Roth A., Jensen H., Garly M.L., et al. Low birth weight infants and Calmette-Guerin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr Infect Dis J 2004, 23(6):544-550.
264. Lau Y.L., Chan S.Y., Turner M.W., et al. Mannose-binding protein in preterm infants: developmental profile and clinical significance. Clin Exp Immunol 1995, 102(3):649-654.
265. Fanaroff A.A., Korones S.B., Wright L.L., et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J 1998, 17(7):593-598.